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study question: Can resveratrol and epigallocatechin-3-gallate (EGCG) inhibit the growth and survival of endometriotic-like lesions in
vivo in a BALB/c model of endometriosis, and in vitro in primary cultures of human endometrial epithelial cells (EECs)?
summary answer: Resveratrol and EGCG exerted a potent inhibitory effect on the development of endometriosis in a BALB/c
murine model and on the survival of EECs.
what is known already: Endometriosis is a common condition associated with infertility and pelvic pain in women of reproduct-
ive age. Resveratrol and EGCG are two polyphenols with anticarcinogenic and antioxidant properties that have been proposed as natural
therapies to treat endometriosis.
study design, size, duration: Fifty-six 2-month-old female BALB/c mice underwent surgical induction of endometriosis. Treat-
ments with resveratrol or EGCG started 15 days post-surgery and continued for 4 weeks. Human biopsies were taken with a metal Novak
curette from the posterior uterine wall from 16 patients with untreated endometriosis and 15 controls who underwent diagnostic laparos-
copy for infertility.
materials, setting, methods: After the treatments, animals were sacrificed and lesions were counted, measured, excised and
fixed. Immunohistochemistry for proliferating cell nuclear antigen and CD34 was performed for cell proliferation and vascularization assess-
ment in the lesions. The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) technique was performed
for apoptosis evaluation. Peritoneal fluid was collected to analyze vascular endothelial growth factor levels. Human EECs were purified from
proliferative-phase endometrial biopsies and cultured. The effect of both polyphenols on cell proliferation was determined by a colorimetric
assay using the CellTiter 96wAQueous One Solution Cell Proliferation Assay kit and on apoptosis by the TUNEL technique, using an In Situ
Cell Death Detection Kit with Fluorescein.
main results: In the mouse model, both treatments significantly reduced the mean number (P , 0.05 versus control) and the volume
of established lesions (P , 0.05 versus control). Treatments consistently statistically significantly diminished cell proliferation (resveratrol P ,
0.01 and EGCG P , 0.05, versus control), reduced vascular density (resveratrol P , 0.01 and EGCG P , 0.001, versus control) and
increased apoptosis within the lesions (resveratrol P , 0.01 and EGCG P , 0.05, versus control). Both compounds induced reduction in
human EEC proliferation (P , 0.05 versus basal) and increased apoptosis (P , 0.05 versus basal) in primary cultures.
limitations: In vitro studies were only carried out in epithelial cells from human eutopic endometrium.
wider implications of the findings: The present findings are promising and will assist the development of novel natural
treatments for endometriosis.
study funding: This study was supported by ANPCYT (PICT 6384 BID 1201 OC-AR) and CONICET (PIP 5471), Argentina. None
of the authors has any conflict of interest to declare.
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Endometriosis is one of the most common benign disorders and
affects 6–10% of women of reproductive age (Giudice and Kao,
2004). The disease is defined as the presence of endometrial glands
and stroma outside the uterine cavity and patients with endometriosis
often suffer from dysmenorrhea, dyspareunia, dysuria and chronic ab-
dominal or pelvic pain, as well as infertility, resulting in a limited quality
of life (Giudice and Kao, 2004). As the disease is estrogen-dependent,
medical therapies are principally aimed at down-regulating ovarian es-
trogen production (Valle and Sciarra, 2003; Mihalyi et al., 2006).
However, it is well known that current medical therapies available
for the treatment of endometriosis have adverse effects that limit
their long-term use. Moreover, recurrence of the disease after the ces-
sation of therapy is very frequent and most patients need to extend
treatment to maintain a hypoestrogenic environment until conception.
Therefore, it is important to keep on looking for new safe and effective
long-term treatments.
Nowadays, natural compounds found in food and plants are being
considered for the treatment of diverse diseases, like cancer, for
example, which shares important similarities with endometriosis
even though the latter is a benign disease (Varma et al., 2004). The
health benefits of green tea, red wine, garlic and fresh fruits have
been described for many years, and their efficiency in the prevention
of diseases has been confirmed by several molecular studies (Cucciolla
et al., 2007; Khan and Mukhtar, 2008). Catechins in green tea and
polyphenols in red wine are responsible for the observed benefits of
these products that are part of our daily diet habits.
Epigallocatechin-3-gallate (EGCG) is the major catechin found in
green tea and has been considered in the last years for the treatment
of different types of cancer, based on its antioxidant, antiangiogenic
and antiproliferative effects (Zaveri, 2006; Khan and Mukhtar, 2008).
Its antimitotic properties lead to the idea that EGCG could be
useful for the treatment of endometriosis. Recent studies showed en-
couraging results in this area (Laschke et al., 2008; Xu et al., 2009,
2011). However, until now there is no evidence of the systemic
effect of oral administration, neither of this compound nor of the
direct effect, on the survival of endometrial epithelial human cells in
primary cultures. One of the aims of our study was to evaluate the
effects of oral administration of EGCG on the growth and survival
of surgically induced endometriosis in immunocompetent BALB/c
mice, considering the importance of the immune system in this path-
ology (Tariverdian et al., 2007, 2009). On the other hand, another
effective compound is resveratrol (trans-3,4′,5-trihydroxystilbene), a
natural phytoalexin produced by some grape species, peanuts and
berries in response to fungal infections or UV radiation (Cucciolla
et al., 2007). The most significant concentrations of resveratrol are
found in the skin of grapes and therefore in red wines but not white
wines. Evidence indicates that this compound has anticarcinogenic,
anti-inflammatory and antioxidant properties as well as pro-apoptotic
and antiangiogenic effects (Brakenhielm et al., 2001; Garvin et al.,
2006). There is only one very recent study that evaluated the effect
of resveratrol on experimental endometriosis in vivo and on the inva-
siveness of endometrial stromal cells in vitro (Bruner-Tran et al., 2011).
The limited evidence available leads to the need of more studies to
elucidate the effect of this polyphenol on the survival of endometrial
epithelial human cells, as well as its effect on endometriosis develop-
ment in an immunocompetent mouse model of the disease.
The aim of our study was to evaluate the effects of these two
natural compounds both in vivo and in vitro on the growth and survival
of experimental endometriosis in a BALB/c mouse model and on




In this study, 56 2-month-old female BALB/c mice were used. All proce-
dures were performed according to the NIH guidelines for the care and
the use of laboratory animals and approved by the Ethics and Research
Committee from the Biology and Experimental Medicine Institute of
Buenos Aires, Argentina. A total of five animals died or had to be sacri-
ficed between 2 and 3 days after surgery because they did not fully
recover from the intervention.
Surgical induction of endometriosis
and treatment
Endometriotic-like lesions were induced through transplantation of one of
the uterine horns to the bowel mesentery as previously described (Bilotas
et al., 2010). Briefly, animals were deeply anesthetized with an intraperito-
neal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). After-
wards, mice underwent laparotomy by a mid-ventral incision to expose
the uterus and the intestine. The right uterine horn was removed and
placed in a Petri dish containing DMEM-F12 (Gibco, Paisley, UK) supple-
mented with 100 IU/ml penicillin and 100 mg/ml streptomycin (Gibco).
The uterine horn was opened longitudinally and then cut into square
pieces measuring 4 mm2. Three equal pieces of tissue were then
sutured onto the serosal layer with a single 6–0 nylon suture (Supralon,
Ethicon, Somerville, NJ, USA). Endometrial tissue was sutured facing the
serosa. The abdomen was then closed with a 5–0 nylon suture.
After surgery, animals were randomly assigned to experiments to test
the effect of resveratrol (R5010, Sigma-AldrichTM Co., Saint Louis, MO,
USA), or EGCG (E4268, Sigma-Aldrich). Treatment was initiated 2
weeks after surgery and continued for 4 weeks. Mice were monitored
daily and no evidence of toxicity was noted based on body weight, food
consumption, grooming behavior or activity levels compared with respect-
ive controls. Besides the estrous cycles were followed cytologically during
treatments to ensure that they do not interfere with reproductive activity.
No differences were detected between controls and treated mice (data
not shown).
Resveratrol treatment
Resveratrol was dissolved in 100% ETOH to make a stock solution of
50 mg/ml. Twenty-nine animals were randomly assigned to three experi-
mental groups: Res I (resveratrol 10 mg/kg in water), Res II (resveratrol
25 mg/kg in water) and control (10% ETOH vehicle). The treatments
were administered daily intraperitoneally.
EGCG treatment
EGCG was dissolved in water to make a stock solution of 20 mg/ml.
Twenty-seven animals were randomly assigned to three experimental
groups: EGCG I (EGCG 20 mg/kg in water), EGCG II (EGCG 100 mg/
kg in water) and control (vehicle only).The treatments were administered
daily by esophageal gavage.
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Evaluation of endometriotic-like lesions
After 4 weeks of treatment, animals were sacrificed by cervical dislocation.
The abdomen was opened by a ventral midline incision. Implantation sites
were localized by the presence of a lesion or by a suture alone. Lesions
were counted and measured in two perpendicular diameters (d , D)
using a caliper. Lesion volumes were determined using the formula:
V ¼ (4/3)pr2R (r and R are the radii, r , R) (Ricci et al., 2011). Then
lesions were excised and fixed in 10% formaldehyde for histological ana-
lysis. Formalin-fixed specimens were paraffin-embedded and cut into
5 mm serial sections. Several sections from each specimen were stained
with hematoxylin-eosin and examined microscopically for the presence
of histological hallmarks of endometriosis. The evaluation of the estab-
lished endometriotic-like lesions was performed by two independent
observers, blinded to the treatment condition.
Immunohistochemistry for proliferating cell
nuclear antigen and CD34
Serial sections of the endometriotic-like lesions were subjected to stand-
ard immunohistochemistry (Meresman et al., 2000). Tissue sections
were incubated overnight with the primary antibody [rabbit antimouse
proliferating cell nuclear antigen (PCNA) polyclonal, 1:300, FL-261,
Santa Cruz Biotechnology, Santa Cruz, CA; or rat antimouse CD34 mono-
clonal, 1:50, ab8158 Abcam, Cambridge, MA, USA] at 48C. After that,
sections were treated for 60 min with the proper secondary biotinylated
antibody (antirabbit IgG, 1:200, B7389 Sigma-Aldrich; or goat antirat IgG
1:500, B7139 Sigma-Aldrich) followed by incubation with streptavidin-
peroxidase (LSAB + System, Dako, Carpinteria, CA, USA). Binding was
visualized by incubating sections with diaminobenzidine and lightly coun-
terstaining with hematoxylin. As a negative control, immunoglobulin of
the same immunoglobulin class and concentration as the primary anti-
bodies was used.
PCNA positive cells were identified by the presence of brown nuclear
reactivity. A total of 300 epithelial cells were counted from representative
fields, considering all lesions and the percentage of PCNA positive cells
was established per mouse, blinded to the treatment condition. All per-
centages were used to get the mean value per group. Any nuclear staining
was regarded as positive.
Staining for CD34 was assessed to study vascular density identifying
blood vessels. The percentage of total area expressing immunoreactivity
for CD34 was established blindly to the treatment condition, by analyzing
10 representative fields from all lesions with the Image J 1.33u software
(NIH, USA). The CD34 positive area was calculated per field and then
averaged per mouse. All percentages were used to get the mean value
per group.
TUNEL assay
For apoptosis quantification, sections were processed for in situ immuno-
localization of nuclei exhibiting DNA fragmentation, by the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling
(TUNEL) technique, using the apoptosis detection kit Apoptag Plus
(Chemicon International, Temecula, CA, USA). Sections were treated
according to the manufacturer’s instructions as previously described
(Meresman et al., 2000). The positive control was provided by the supplier
of the kit. As a negative control, a number of tissue samples were
subjected to treatment without TdT. Finally, sections were counterstained
with hematoxylin. A total of 300 epithelial cells were counted from
representative fields, considering all lesions, and the percentage of
TUNEL positive cells was established per mouse, blinded to the
treatment condition. All percentages were used to get the mean value
per group.
Quantification of vascular endothelial growth
factor
Peritoneal fluid was collected by rinsing the abdominal cavity with 1.5 ml of
saline and centrifuged at 48C during 10 min at 1500 rpm. Supernatants
were stored at 2208C until assayed for vascular endothelial growth
factor (VEGF) using a commercial enzyme-linked immunoassay (ELISA)
kit according to the manufacturer’s instructions (QIA52, Calbiochem,
EMD Chemicals Inc., USA). The sensitivity level for the VEGF ELISA was
3 pg/ml. The intra-assay variability for VEGF was +4.3% while the inter-
assay variability was +5.7%. All samples were assessed in triplicate.
Collection of human biopsies
A total of 31 patients in reproductive age who underwent diagnostic lapar-
oscopy for infertility participated in this study: 16 with untreated endomet-
riosis (Stages I and II, according to the Revised American Society for
Reproductive Medicine Classification [ASRM, 1997]) and 15 controls.
Confirmation of the disease was performed by histological documentation.
Control subjects were infertile women without endometriosis or any in-
fectious or non-infectious pathology that could affect the evaluated cell
population, with tubal factor or unexplained infertility, undergoing diagnos-
tic laparoscopy. To avoid false negatives, only patients who did not com-
plain of pelvic pain were considered for the control group. All patients
were infertile, showed regular menstrual cycles and had not received
any hormonal medical treatment for the last 6 months. All subjects
signed informed consent prior to evaluation. Biopsies of eutopic endomet-
rium were obtained from all subjects in the proliferative phase, as
described previously (Meresman et al., 2000). Biopsies were taken with
a metal Novak curette from the posterior uterine wall. This study was
approved by the Ethics and Research Committee from the Biology and Ex-
perimental Medicine Institute of Buenos Aires, Argentina.
Isolation and culture of EECs
EECs were obtained from eutopic endometrial biopsies of patients with
endometriosis and control subjects. The tissue was immediately placed
into a sterile tube with culture medium and processed within 3 h of collec-
tion. Epithelial cells were enzymatically separated and isolated by succes-
sive centrifugation, and primary cultures were established for in vitro
studies as previously described (Meresman et al., 2003a,b). Briefly,
tissue was minced, washed and placed in MEM Eagle D-Valine Modified
w/L-Glutamine, D-Valine medium (USBiological, MA, USA) supplemented
with penicillin 100 IU/ml, streptomycin 100 mg/ml and amphotericin
B 25 mg/ml (Gibco) with collagenase 0.5 mg/ml (type I, Gibco). After
2 h of incubation at 378C in a 5% CO2 atmosphere, the resulting suspen-
sion was centrifuged at 100 g for 5 min. The pellet containing epithelial
glands was resuspended in culture medium and spun again at 100 g for
5 min. The final pellet mainly contained epithelial cells. The enriched epi-
thelial fraction was cultured with MEM D-Val supplemented with 10% fetal
bovine serum (FBS; Gibco) and grown to sub-confluence (70–80%) at
378C for 48 h before the experiments. In all cases, each biopsy was utilized
to run one or more experiments and there was no pooling of samples.
It has been previously shown that this method guarantees purity of EECs
in culture (Meresman et al., 2003a,b). Culture’s purity was 85–90% for
epithelial cells as determined by cytokeratin staining (Supplementary
data, Fig. S1).
Cell proliferation assay in primary cultures
After purification, EECs (5 × 104/well) were plated in 96-well culture
plates with MEM D-Val supplemented with 10% FBS and incubated at
378C in a 5% CO2 atmosphere. After 48 h, cultures were washed and
incubated with different concentrations of resveratrol (0, 25, 50 and
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100 mM) or EGCG (0, 20, 40, 80 and 100 mM) in fresh medium supple-
mented with 2.5% FBS. Basal conditions (0m M) were performed by incu-
bating EECs with the final concentration of dimethyl sulfoxide (DMSO;
D5879, Sigma-Aldrich), the vehicle used to reconstitute both compounds.
EEC proliferation was determined by a colorimetric assay using the CellTi-
ter 96wAQueous One Solution Cell Proliferation Assay kit (Promega
Corp., Madison, WI, USA). After 24 h of treatment, 20 ml of One Solution
Reagent was added to each well and incubated for 2 h at 378C. Absorb-
ance was measured at 490 nm using a multi-well plate reader. The One
Solution Reagent contains MTS tetrazolium (3-[4,5-dimethylthiazol-2-yl]
-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium), which
is bioreduced by cells into a formazan product. The absorbance of the for-
mazan product is directly proportional to the number of living cells. Experi-
ments were conducted with replicates of six wells per treatment
condition. Similar experiments were conducted with cells purified from
nine biopsies from women with endometriosis and seven biopsies from
control subjects. Cell proliferation was expressed as a percentage of
basal conditions in each experiment.
Apoptosis assay in primary cultures
EECs (1 × 105/well) were plated in Lab-Tek eight-well culture chambers
(Nalge Nunc, Naperville, IL, USA) with MEM D-Val supplemented with
10% FBS. After 48 h, cultures were washed and incubated with different
concentrations of resveratrol (0, 25, 50 and 100 mM) or EGCG (0, 20,
40, 80 and 100 mM) in medium supplemented with 2.5% FBS. Basal con-
ditions (0 mM) consisted of the final concentration of DMSO as explained
above. Cells were incubated for 24 additional hours and then were fixed in
4% paraformaldehyde to assess the percentage of apoptotic cells by the
TUNEL technique, using an In Situ Cell Death Detection Kit with Fluores-
cein (Roche 11684795910, Roche Diagnostics GmbH Roche Applied
Science, Mannheim, GE, USA) according to the manufacturer’s protocol.
Lab-Tek slides were stained with 4′-6′ diamino-2-phenyllindole (DAPI)
to label nuclei and then mounted in Vectashield mounting medium
(H-1000, Vector Laboratories Inc., Burlingame, CA, USA). The apoptotic
index was evaluated using a fluorescence microscope. The total number of
fluorescein isothiocyanate (FITC)-positive nuclei from 300 DAPI-positive
nuclei was determined by analyzing representative fields under each treat-
ment condition. Similar experiments were conducted with cells purified
from seven biopsies from women with endometriosis and eight biopsies
from control subjects. Results were expressed as a percentage of FITC/
TUNEL positive to total DAPI-stained nuclei.
Statistical analysis
Statistical analyses were performed using GraphPad PRISM Software V4.0
(GraphPad Software Inc., San Diego, CA, USA). Statistical comparisons
between groups were performed using parametric one-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparison test, or non-
parametric one-way ANOVA followed by Dunn’s multiple comparison
test. TUNEL and PCNA positive cells were counted blindly, by two inde-
pendent observers. Results were expressed as mean+ SEM. In all cases,
statistical significance was considered to be P , 0.05.
Results
Effect of resveratrol and EGCG on
endometriotic-like lesion growth
The number of established lesions observed per mouse was signifi-
cantly reduced by the higher (25 mg/kg/day) dose of resveratrol
(P , 0.05 versus control). However, EGCG was able to reduce the
number of established lesions at either 20 or 100 mg/kg/day (P ,
0.05 versus control). The results are displayed in Fig. 1A. Regarding
the volume of developed lesions, both treatments caused a statistically
significant reduction in lesion size. As seen in Fig. 1B, resveratrol only
diminished their volume at 25 mg/kg/day (P , 0.05 versus control),
whereas EGCG treatment was able to significantly diminish lesion
size at either 20 or 100 mg/kg/day (I P , 0.05 versus control; II
P , 0.01 versus control).
Effect of resveratrol and EGCG treatments
on cell proliferation and apoptosis
in endometriotic-like lesions
Cell proliferation was evaluated by immunohistochemistry for PCNA
(Fig. 2). Treatment with both doses of resveratrol and EGCG
caused a decrease in epithelial cell proliferation compared with the
control group (Res I P , 0.01 versus control; Res II P , 0.001
versus control; EGCGI P , 0.05 versus control; EGCGII P , 0.01
versus control).
Complementary to the observed results for cell proliferation, all
treatments significantly increased the apoptotic index in epithelial
cells of endometriotic-like lesions (Res I P , 0.01 versus control;
Res II P , 0.001 versus control; EGCGI P , 0.05 versus control;
EGCGII P , 0.01 versus control), assessed by the TUNEL technique
(Fig. 3).
Effect of resveratrol and EGCG on VEGF
levels and vascular density
To determine the vascular density, blood vessels in endometriotic-like
lesions were immunostained with CD34 antibody, and the percentage
of vascular area was quantified (Fig. 4). In both cases, the
treatment-inhibitory effect was clearly associated with an important
decrease in the vascular density (Res I/II P , 0.01 versus control;
EGCGI/II P , 0.001 versus control).
After treatments, peritoneal fluid was collected and levels of VEGF
were assessed by ELISA. Treatment with EGCG (both doses) signifi-
cantly decreased VEGF levels in the peritoneal fluid (I P , 0.001
versus control; II P , 0.05 versus control). However, resveratrol did
not significantly reduce the peritoneal VEGF levels at any of the
doses tested (Fig. 5).
Effects of resveratrol and EGCG on EEC
proliferation and apoptosis
The effects of different concentrations of resveratrol and EGCG on
EEC proliferation are displayed in Fig. 6A and B. After exposure to
50 and 100 mM of resveratrol, the EECs showed a significantly
lower percentage of cell proliferation (P , 0.05 and P , 0.01 respect-
ively, versus basal) in cultures from both control women (Fig. 6A(i))
and endometriosis patients (Fig. 6B(i)). EGCG treatment showed a sig-
nificant inhibition with all assayed concentrations (40, 80 and 100 mM),
excluding the lowest one (20 mM), which had no significant effect on
basal cell proliferation (Fig. 6A(ii)–B(ii)). The same significant effect
was observed in cultures from endometriosis patients (P , 0.05,
P , 0.01, P , 0.001 versus basal, respectively) and from control
women (P , 0.01 versus basal).
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The effects of different concentrations of resveratrol and EGCG on
EEC apoptosis are displayed in Fig. 7A and B. Complementary to the
results obtained from cell proliferation experiments, resveratrol 50
and 100 mM enhanced apoptosis in EEC from control women (P ,
0.05 and P , 0.01 versus basal, respectively). However, in endomet-
riosis EEC cultures, 100 mM was the only concentration that showed
a significant effect (P , 0.01 versus basal). Regarding EGCG treat-
ment, 40, 80 and 100 mM assayed doses showed a significant effect
on endometrial growth enhancing apoptosis in EEC from control sub-
jects (40/80 mM P , 0.05 versus basal; 100 mM P , 0.01 versus
basal), as well as in EEC from endometriosis patients (P , 0.01
versus basal).
Discussion
Treatment of endometriosis-associated symptoms typically requires
surgical as well as medical intervention (Crosignani et al., 2006).
Even though current available medical therapies are not curative per
se, they are a mainstay of pain suppression and lesion regression in
women suffering from this pathology. However, efforts are still being
focused on the improvement and promotion of new treatments
with higher efficacy and fewer side effects.
Over the last decade, the use of herbal compounds, multivitamin
supplements, minerals and other plant-derived components to treat
different diseases has been growing more prevalent. In the last
Figure 1 The effect of resveratrol and EGCG on the number (A) and volume (B) of endometriotic-like lesions. Mice with surgically induced endo-
metriosis were treated everyday starting on post-surgery day 15 with: (i) resveratrol (Res I 10 mg/kg–Res II 25 mg/kg) or vehicle (control); (ii) EGCG
(EGCG I 20 mg/kg–EGCG II 100 mg/kg) or vehicle (control). After 4 weeks of treatment, mice were sacrificed and established lesions were counted
and measured with calipers. The number of established lesions (.0 mm3) per mouse was calculated for each treatment group. The volume for each
lesion was calculated with the formula V ¼ (4/3)pr2R. Volume values of all developed lesions per mouse were averaged and the mean was calculated
for each treatment group. Results are expressed as mean+ SEM. *P , 0.05/**P , 0.01 versus control. n ¼ 8 (Res control), 10 (Res I), 10 (Res II), 8
(EGCG control), 9 (EGCG I), 6 (EGCG II).(C) Photographs illustrating the endometriotic-like lesions of (a) Res control, (b) Res I, (c) Res II, (d) EGCG
control, (e) EGCG I and (f) EGCG II are displayed. Black arrow heads indicate the established lesions at the end of treatments.
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Figure 2 The effect of resveratrol and EGCG on endometriotic-like lesion cell proliferation. Mice with surgically induced endometriosis were
treated everyday starting on post-surgery day 15 with: (A) resveratrol (Res I 10 mg/kg–Res II 25 mg/kg) or vehicle (control), (B) EGCG (EGCG
I 20 mg/kg–EGCG II 100 mg/kg) or vehicle (control). After 4 weeks of treatment, mice were sacrificed and lesions were dissected away, formalin-
fixed, paraffin-embedded and cut into sections. Cell proliferation was evaluated by immunohistochemistry for PCNA and was quantified in the epi-
thelial fraction as a percentage of PCNA positive cells. Results are expressed as mean+ SEM. *P , 0.05/**P , 0.01/***P , 0.001 versus control.
n ¼ 6 (Res control), 6 (Res I), 5 (Res II), 6 (EGCG control), 6 (EGCG I), 5 (EGCG II). (C) Photomicrographs of PCNA immunostaining of (i) Res
control, (ii) Res I, (iii) Res II, (iv) EGCG control, (v) EGCG I and (vi) EGCG II are displayed. As a negative control (inset (iii) and (vi)) an immunoglobulin
of the same class and concentration as the primary antibody was used. Magnification: 400×.
Figure 3 Effect of resveratrol and EGCG on endometriotic-like lesion apoptosis. Mice with surgical induced endometriosis were treated everyday
starting on post-surgery day 15 with: (A) resveratrol (Res I 10 mg/kg–Res II 25 mg/kg) or vehicle (control), (B) EGCG (EGCG I 20 mg/kg–EGCG II
100 mg/kg) or vehicle (control). After 4 weeks of treatment, mice were sacrificed and lesions were dissected away, formalin-fixed, paraffin-embedded
and cut into sections. Apoptosis was assessed by TUNEL technique and was quantified in the epithelial fraction as percentage of TUNEL positive cells.
Results are expressed as mean+ SEM. *P , 0.05/**P , 0.01/***P , 0.001 versus control. n ¼ 6 (Res control), 6 (Res I), 5 (Res II), 6 (EGCG
control), 6 (EGCG I), 5 (EGCG II). (C) Photomicrographs of TUNEL staining of (i) Res control, (ii) Res I, (iii) Res II, (iv) EGCG control, (v)
EGCG I and (vi) EGCG II are displayed. Blue arrow heads indicate apoptotic cells in the epithelial fraction. Negative controls (inset (i) and (iv))
were incubated in the absence of TdT. Magnification: 400×.
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years, it has been shown that complementary and alternative medicine
such as medicinal herbs and other botanicals with anti-inflammatory
properties could be useful in the treatment of endometriosis-
associated pain (Wieser et al., 2007).
EGCG from green tea and resveratrol from red wine and grapes
are some of the natural options that have lately been considered to
treat different types of cancer (Aggarwal et al., 2004; Zaveri, 2006;
Cucciolla et al., 2007; Khan and Mukhtar, 2008; Chen et al., 2011).
Nowadays green tea is considered one of the most promising
dietary agents for the prevention and treatment of cancer. Previous
studies have shown that EGCG inhibited the growth of various
human cancer cells such as cervical cancer cells (Qiao et al., 2009)
and ovarian cancer cells (Rao and Pagidas, 2010), among others, as
well as uterine leiomyoma cells (Zhang et al., 2010a,b). Not many
works have been reported on the EGCG ability to inhibit the onset
of endometriosis (Xu et al., 2009, 2011; Bruner-Tran et al., 2011).
However, these recent few studies have been developed in a nude
mouse model; hence the immune system’s role was not considered.
Resveratrol affects a large array of biological activities and its mechan-
isms of action are clearly dose dependent (Szende et al., 2000; Bhat
et al., 2001; Harikumar and Aggarwal, 2008; Athar et al., 2009). Resver-
atrol’s effects have been studied in chemoprevention and treatment of
hepatocellular carcinoma (Bishayee et al., 2010), breast cancer (Garvin
et al., 2006), Lewis lung carcinoma (Kimura and Okuda, 2001) and liver
cancer (Wu et al., 2004), with positive results.
Considering that patients usually consult for pain symptoms or dif-
ficulty in achieving pregnancy, after endometriotic lesions have already
established, we look for possible therapies to treat established lesions.
Taking all these data into account, one of the aims of the present study
was to evaluate the effect of two natural therapies with resveratrol and
EGCG, during the development of established endometriotic-like
lesions experimentally induced in BALB/c mice.
We observed that both resveratrol and EGCG exerted a significant
inhibition on the development of endometriotic-like lesions, reducing
the size of the lesions, by diminishing cell proliferation and increasing
apoptotic levels. Moreover, both treatments were able to decrease
the number of established lesions per mouse. It is remarkable that a
treatment that begins 15 days after surgery can affect the development
and maintenance of already established endometriotic-like lesions
rather than just their establishment.
Although EGCG has previously been reported to exert distinct
anticancer effects (Khan and Mukhtar, 2008; Zhang et al., 2010a),
and some recent works showed its antiangiogenic effects on endomet-
riosis (Xu et al., 2009, 2011), this is to our knowledge, the first study
demonstrating the effectiveness of oral administration in a murine
model of endometriosis using immunocompetent BALB/c mice. In
addition, we proved the EGCG antiproliferative and proapoptotic
effects on endometriosis in accordance with those previously
observed in other models (Rao and Pagidas, 2010; Zhang et al.,
2010b), and confirmed the EGCG antiangiogenic effects, reflected
Figure 4 Effect of resveratrol and EGCG on endometriotic-like lesion vascular density. Mice with surgical induced endometriosis were treated
everyday starting on post-surgery day 15 with: (A) resveratrol (Res I 10 mg/kg–Res II 25 mg/kg) or vehicle (control), (B) EGCG (EGCG I
20 mg/kg–EGCG II 100 mg/kg) or vehicle (control). After 4 weeks of treatment, mice were sacrificed and lesions were dissected away, formalin-
fixed, paraffin-embedded and cut into sections. Vessels were identified using CD34 staining of the vascular endothelium and quantified as percentage
area. Results are expressed as mean+ SEM. **P , 0.01/***P , 0.001 versus control. n ¼ 5 (Res control), 6 (Res I), 6 (Res II), 5 (EGCG control), 6
(EGCG I), 5 (EGCG II). (C) Photomicrographs of CD34 immunostaining of (i) Res control, (ii) Res I, (iii) Res II, (iv) EGCG control, (v) EGCG I and (vi)
EGCG II are displayed. As a negative control (inset (iii) and (vi)) an immunoglobulin of the same class and concentration as the primary antibody was
used. Magnification: 400×.
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by a reduction in the levels of VEGF in peritoneal fluid and in the vas-
cular density of lesions.
Bruner-Tran et al. (2011) have recently demonstrated that resvera-
trol is able to reduce the development of experimental endometriosis
in a nude mouse model. They related these protective effects of
resveratrol to a reduction in endometrial cell proliferation and an in-
crease in cell death. However, the effects of resveratrol on the prolif-
eration of endometriotic tissues were not so clear: they found a
decrease of MKI67 expression but an increase in PCNA staining,
both proliferation markers. In this study, we observed and quantified
a clear and significant decrease in cell proliferation by PCNA staining
after treatment with resveratrol.
We and other authors have described the importance of angio-
genesis for the development of endometriosis and it was proposed
that the suppression of blood vessel development by the inhibi-
tion of VEGF may be a novel therapeutic approach for this path-
ology (Nap et al., 2004; Ricci et al., 2011). In an earlier study,
Brakenhielm et al. (2001) showed that the suppression of angiogen-
esis could be at least one of the mechanisms involved in the antitu-
mor effect of resveratrol and posited that the consumption of
resveratrol could be beneficial in the prevention of angiogenesis-
dependent diseases. There are extensive studies showing the anti-
angiogenic effect of resveratrol in different cancer models (Garvin
et al., 2006; Hu et al., 2007; Trapp et al., 2010) but this is the
first report on endometriosis. In this study, we confirmed its
antiangiogenic properties, obtaining a reduction in the vascular
density of the endometriotic-like lesions. Even though we did not
observe a significant decrease in VEGF levels in the peritoneal cav-
ities of treated mice, the antiangiogenic effects of resveratrol could
be mediated by other proangiogenic factors. Moreover, resveratrol
could be regulating the expression of VEGF receptors instead of
VEGF levels.
On the other hand, according to our knowledge, this is the first
report evaluating the effects of resveratrol and EGCG on the survival
of EECs from human biopsies, and it clearly demonstrates that treat-
ment with both polyphenols effectively reduce cell proliferation and
induce cell death. Only one study carried out by Bruner-Tran et al.
studied the effect of resveratrol on the invasiveness of endometrial
stromal cells, but in this work only endometrial tissue from women
without endometriosis was used. The authors made clear the need
of further studies to also evaluate the effects of resveratrol on
eutopic endometrial tissues from women with endometriosis (Bruner-
Tran et al., 2011).
In the present study and in previous works performed in our labora-
tory (Meresman et al., 2003a; Olivares et al., 2008), we found no sig-
nificant differences in the percentage of cell proliferation and apoptotic
cells between endometrial cell cultures from endometriosis patients
and control women. In spite of the fact that the in vitro response of
the cells employed in this investigation may not be identical to its
physiological response, the use of endometrial eutopic cells in short-
term culture as a model for endometriosis research has been well
approved and documented previously (Olivares et al., 2008).
Green tea represents one of the most widely consumed beverages
in the world; however, green tea extracts are also available as nutrient
supplements, offering an easy way of achieving the required EGCG
doses without having to take innumerable tea cups. In the same
way, long-term consumption of resveratrol-enriched wine products
is not a recommendable treatment due to the alcohol content; so
other food products should be considered as alternative resveratrol
sources, as well as compressed pills with the necessary dose. On
the other hand, more studies are needed to determine the effective
human plasma concentrations of EGCG or resveratrol to achieve
the inhibition of endometriotic-like lesion development.
Better understanding of the basic mechanisms of action of EGCG
and resveratrol, as well as their bioavailability is needed to determine
the potential usefulness of these natural compounds as endometriosis
preventive agents.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals
.org/.
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Figure 5 VEGF peritoneal fluid levels. Mice with surgically induced
endometriosis were treated everyday starting on post-surgery day 15
with: (A) resveratrol (Res I 10 mg/kg–Res II 25 mg/kg) or vehicle
(control), (B) EGCG (EGCG I 20 mg/kg–EGCG II 100 mg/kg) or
vehicle (control). After 4 weeks of treatment, mice were sacrificed
and the peritoneal fluid was collected. Levels of VEGF were assessed
by ELISA. *P , 0.05/***P , 0.001 versus control. n ¼ 8 (Res
control), 10 (Res I), 9 (Res II), 8 (EGCG control), 7 (EGCG I), 6
(EGCG II).
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Figure 6 The effect of resveratrol and EGCG on cell proliferation in EEC cultures. EECs from seven control women (A) and nine patients with
endometriosis (B) were grown for a pre-confluent period of 48 h and then treated for 24 h with resveratrol (i), EGCG (ii) or vehicle control
(basal) (i and ii). Cell proliferation was assessed by an MTS assay. Values of each treatment condition are expressed as a percentage of basal cell
proliferation (set as 100%). Results are expressed as mean+ SEM. *P , 0.05/**P , 0.01/***P , 0.001 versus basal.
Figure 7 The effect of resveratrol and EGCG on apoptosis in EEC cultures. EECs from eight control women (A) and seven patients with endo-
metriosis (B) were grown for a pre-confluent period of 48 h and then treated for 24 h with resveratrol (i), EGCG (ii) or vehicle control (0 mM) (i
and ii). Apoptosis was assessed by the TUNEL technique. Values of each treatment condition are expressed as a percentage of FITC/TUNEL positive
nuclei from 300 total DAPI-stained nuclei. Results are expressed as mean+ SEM. *P , 0.05/**P , 0.01 versus control (0 mM).
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